

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/551,876
				Filing Date	September 30, 2005
				First Named Inventor	Brian G. Condie
				Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	18377-0063

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
KKH		5,114,926 A	05-19-1992	Frindel, et al.	
		5,453,357	09-26-1995	Hogan	
		5,589,376	12-31-1996	Anderson, et al.	
		5,753,506	05-19-1998	Johe	
		5,766,948	06-16-1998	Gage, et al.	
		5,780,300	07-14-1998	Artavanis-Tsakonas, et al.	
		5,843,780	12-01-1998	Thomson	
		5,851,832	12-22-1998	Weiss, et al.	
		5,958,767	09-28-1999	Snyder, et al.	
		5,968,829	10-19-1999	Carpenter	
		6,200,806	03-13-2001	Thomson	
		6,562,619	05-13-2003	Gearhart	
		2002/0119565 A1	08-29-2002	Clarke, et al.	
		2002/0146678 A1	10-10-2002	Benvenisty, Nissim	
		2003-0008392 A1	01-09-2003	Thomson, James A.	
		2003/0022251 A1	01-30-2003	Fuchs, et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Patent Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶	
		Country Code ³ Number ⁴ Kind Code ² (if known)					
			WO 97/32033	02-28-1996	Vanderbilt University		
			WO 98/43679	03-31-1998	The Johns Hopkins University School of Medicine		
			WO 99/32606	12-18-1998	Brustle		
			WO 99/53021	04-09-1999	Bresagen, Ltd.		
			WO 00/27995	11-09-1999	Reubinoff		
			WO 01/51611	01-12-2001	Bresagen Limited		
		WO 02/77204	03-25-2002	Axordia Limited			

Examiner Signature	Kevin K. Hill	Date Considered	September 19, 2007
--------------------	---------------	-----------------	--------------------

*EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/551,876
		Filing Date	September 30, 2005
		First Named Inventor	Brian G. Condie
		Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	18377-0063	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KKH		CAPOBIANCO, <i>et al.</i> , (1997), "Neoplastic Transformation by Truncated Alleles of Human <i>NOTCH1</i> / <i>TAN1</i> and <i>NOTCH2</i> ," Molecular and Cellular Biology 17:6265-6273.	
		CHURCHER, <i>et al.</i> , (2003), "A New Series of Potent Benzodiazepine γ -Secretase Inhibitors," Bioorg. Med. Chem. Lett. 13:179-183.	
		CHURCHER, <i>et al.</i> , (2003), "Design and Synthesis of Highly Potent Benzodiazepine γ -Secretase Inhibitors: Preparation of (2S, 3R)-3-(3,4-Difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl) butyramide by Use of an Asymmetric Ireland-Claisen Rearrangement," J Med. Chem. 46:2275-78.	
		DAS, <i>et al.</i> , (2003), "Designed Helical Peptides Inhibit an Intramembrane Protease," J Am. Chem. Soc. 125:11794-11795.	
		DOVEY, <i>et al.</i> , (2001), "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," Journal of Neurochemistry 76, 173-181.	
		ELLISEN, <i>et al.</i> , (1991), "TAN-1, the Human Homolog of the Drosophila <i>Notch</i> Gene, Is Broken by Chromosomal Translocations in T Lymphoblastic Neoplasms," Cell 66:649-661.	
		ESLER, <i>et al.</i> , (2000), "Transition-state analogue inhibitors of γ -Secretase bind directly to presenilin-1," Nat. Cell Biol. 2:428-434.	
		ESLER, <i>et al.</i> , (2002), "Activity-dependent isolation of the presenilin- γ -Secretase complex reveals nicastrin and a γ substrate," PNAS 99:2720-2725.	
		IVANOVA, <i>et al.</i> , (2002), "A Stem Cell Molecular Signature," Science 298:601-604.	
		JANG, <i>et al.</i> , (2000), "Notch signaling as a target in multimodality cancer therapy," Current Opinion Molecular Therapy 2:55-65.	
		JHAPPEN, <i>et al.</i> , (1992), "Expression of an activated <i>Notch</i> -related <i>int-3</i> transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands," Genes and Development 6:345-355.	
		JOUTEL, <i>et al.</i> , (1998), "Notch signalling pathway and human disease," Seminars in Cell and Developmental Biology 9:619-625.	
		NICOLAS, <i>et al.</i> , (2003), "Notch1 functions as a tumor suppressor in mouse skin," Nature Genetics 33:416-421.	
		RAMALHO-SANTOS, <i>et al.</i> , (2002), "'Stemness': Transcriptional Profiling of Embryonic and Adult Stem Cells," Science 298:597-600.	
		RANGARAJAN, <i>et al.</i> , (2001), "Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation," EMBO Journal 13:3427-3436.	
		RISHTON, <i>et al.</i> , (2000), "Fenchylamine Sulfonamide Inhibitors of Amyloid β Peptide Production by the γ -Secretase Proteolytic Pathway: Potential Small-Molecule Therapeutic Agents for the Treatment of Alzheimer's Disease," J Med. Chem. 43:2297-2299.	
		ROBBINS, <i>et al.</i> , (1992), "Mouse Mammary Tumor Gene <i>int-3</i> : a Member of the <i>notch</i> Gene Family Transforms Mammary Epithelial Cells," Journal of Virology 66:2594-2599.	
		SHEARMAN, <i>et al.</i> , (2000), "L-685,458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid β -Protein Precursor γ -Secretase Activity," Biochemistry 39:8698-8704.	
		WEIJZEN, <i>et al.</i> , (2002), "Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells," Nature Med. 8:979-986.	
		WOLFE, <i>et al.</i> , (1999), "Peptidomimetic Probes and Molecular Modeling Suggest That Alzheimer's γ -Secretase Is an Intramembrane-Cleaving Aspartyl Protease," Biochemistry 38:4720-4727.	
		ZAGOURAS, <i>et al.</i> , (1995), "Alterations in Notch signaling in neoplastic lesions of the human cervix," Proc. Natl. Acad. Sci. 92:6414-6418.	
Examiner Signature	Kevin K. Hill	Date Considered	September 19, 2007

*EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.